ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
45 announcements with these filters
Dr. Reddy’s Laboratories will hold a board meeting on October 23, 2026, to approve the standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Reddy's signed an exclusive distribution agreement with Takeda for Qdenga dengue vaccine in India's private market. No upfront consideration stated; availability expected H1 2027.
Dr. Reddy's confirmed a news report regarding a voluntary licensing agreement with Gilead Sciences for an HIV prevention drug, noting it is not material.
Dr. Reddy's Laboratories received two observations from the USFDA following a records assessment of its API manufacturing facility in Jiutepec, Mexico.
Dr. Reddy's Laboratories allotted 375 equity shares to employees upon the exercise of stock options under its ESOP scheme.
Dr. Reddy's Laboratories allotted 4,110 equity shares to employees under its 2002 Employee Stock Option Scheme. The shares rank pari passu with existing equity.
ICICI Prudential Mutual Fund acquired 7,12,884 shares of Dr. Reddy's Laboratories via the open market. This transaction increased the fund's total stake to 5.037%.
Dr. Reddy's Laboratories announced the resignation of Deepak Sapra, CEO of API and Services, effective November 12, 2026.
Dr. Reddy's Laboratories has terminated its distribution and promotion agreement with Novartis India Limited following a change in NIL's controlling shareholding.
Dr. Reddy's Laboratories received a Form 483 with three observations following a USFDA inspection at its Srikakulam FTO-SEZ unit, which the company will address.
Dr. Reddy's clarified a news report regarding Thailand's approval of its antibiotic NULZOLVENCE. The company confirmed the reports are correct and based on a joint press release.
Q1FY27 revenue fell 5.6% YoY to ₹8,071 Cr due to lower Lenalidomide sales. EBITDA margin at 12.5% (15.4% ex-one-offs) was hit by semaglutide API issues and Middle East conflict costs.
Dr. Reddy's Laboratories concluded its 42nd Annual General Meeting on July 23, 2026, with shareholders approving all agenda items, including a final dividend of ₹8 per share.
Q1FY27 revenues reached ₹8,071 Cr with 12.5% EBITDA margin. Results were significantly impacted by a ₹240 Cr semaglutide API charge; underlying EBITDA margin before this impact was 15.4%.
Dr. Reddy's Laboratories granted 15,933 stock options under its 2018 employee stock option scheme. The grant follows approval from the company's compensation committee.
Dr. Reddy's Laboratories appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and appointed Deloitte Haskins & Sells, LLP for US reporting.
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,100 Cr (-5.5% YoY) and net profit of ₹435.6 Cr (-69.1% YoY) for Q1 FY27.
Dr Reddys Laboratories Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details holdings of promoters, institutions, and public shareholders.
Management discloses a significant manufacturing setback for Semaglutide injection due to out-of-specification impurity levels during scale-up, causing a temporary multi-month supply halt.
Dr. Reddy’s Laboratories disclosed that certain semaglutide batches are out of specification, causing a delay in commercial supplies. The company is investigating the issue.
Dr. Reddy's sent letters to shareholders providing a link to the FY 2025-26 Integrated Annual Report. The notice includes details for the 42nd AGM.
Dr. Reddy's Laboratories notified the 42nd AGM on July 23, 2026. The meeting will be held via video conferencing.
Dr. Reddy's Laboratories has submitted its Integrated Annual Report for FY 2025-26. The report includes corporate overviews, strategic reviews, and statutory reports.
USFDA completed a pre-license inspection at Dr Reddy's Bachupally facility. The company received a Form 483 with seven observations.
Dr. Reddy's launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the U.S. This first-to-market launch strengthens its oncology portfolio and patient access.
Dr. Reddy's Laboratories allotted 12,100 equity shares under its Employee Stock Option Schemes. The allotment increases the company's total paid-up share capital.
Dr. Reddy's Laboratories allotted 12,100 equity shares following the exercise of employee stock options. The shares rank pari-passu with existing equity, slightly increasing the total paid-up capital.
Dr. Reddy's Laboratories filed its FY2026 Annual Report in Form 20-F with the US SEC. The report contains consolidated financial statements prepared under IFRS standards.
Dr. Reddy's Laboratories submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The independent report confirms regulatory compliance with no significant deviations.
Dr. Reddy's senior management will ring the NYSE Closing Bell on May 29, 2026. The ceremony celebrates the company's 25th anniversary of listing on the exchange.